-
Citing ‘capacity constraints,’ Novo Nordisk plots global wind-down of human insulin pen production
By Fraiser Kansteiner Nov 14, 2024 2:13pm As sales of Novo Nordisk’s GLP-1 drugs for diabetes and […]
-
ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
A new trend has emerged at this year’s American Society of Clinical Oncology conference: the possibility of replacing decades-old chemotherapy with novel approaches. “We want to be part of that wave,” AbbVie Pedro Valencia, Ph.D., AbbVie’s vice president of solid tumor pipeline strategy and execution, told Fierce Biotech onsite in Chicago. “This is the ASCO…
-
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
KEY POINTS Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results. Their prospects through 2030 look excellent thanks to some major products.
Pharma Business
Archive
Categorise
Recent Posts
- Citing ‘capacity constraints,’ Novo Nordisk plots global wind-down of human insulin pen production
- NIH, MSKCC researchers publish AI model for predicting immunotherapy responses
- ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
- Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
- 8 Biotech Companies in Chicago Cultivating the City’s Life Sciences Scene
